Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Alefacept. Biogen.

Anthony D Ormerod¹

¹Aberdeen University and University Hospitals, Department of Dermatology, Aberdeen Royal Infirmary, Aberdeen, AB25 2ZN, UK. a.d.ormerod@arh.grampian.scot.nhs.uk

Current Opinion in Investigational Drugs (London, England : 2000)

|July 2, 2003

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Current prescribing for pyoderma gangrenosum in the UK and access to biologic medications: results from a UK Dermatology Clinical Trials Network survey of dermatologists.

Clinical and experimental dermatology·2024

Same author

Predicting the outcome of psoriasis treatment.

The British journal of dermatology·2022

Same author

TGFβ2 Induces the Soluble Isoform of CTLA-4 - Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma.

Frontiers in immunology·2022

Same author

Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).

The Journal of investigative dermatology·2017

Same author

Is speed of healing a good predictor of eventual healing of pyoderma gangrenosum?

Journal of the American Academy of Dermatology·2016

Same author

Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: A prospective cohort study.

Journal of the American Academy of Dermatology·2016

Alefacept, a novel T-cell inhibitor, was launched for moderate-to-severe chronic plaque psoriasis. This biologic therapy targets T-cell activity by blocking CD2 interaction, offering a new treatment avenue.

Area of Science:

Immunology
Dermatology
Pharmacology

Background:

Psoriasis is a chronic autoimmune skin condition characterized by T-cell mediated inflammation.
Current treatments for moderate-to-severe psoriasis have limitations, necessitating novel therapeutic approaches.

Purpose of the Study:

To introduce alefacept, a new biologic therapy for psoriasis.
To detail the mechanism of action and market launch of alefacept.

Main Methods:

Alefacept is a fusion protein targeting Lymphocyte function-associated antigen-3 (LFA-3) and CD2.
It inhibits T-cell activation and proliferation by blocking the LFA-3/CD2 pathway.

Main Results:

Alefacept was developed and launched by Biogen for psoriasis treatment.

Related Experiment Videos

The drug received US market approval for adults with moderate-to-severe chronic plaque psoriasis in February 2003.

Conclusions:

Alefacept represents a targeted biologic therapy for psoriasis.
Biogen's launch signifies a new option for patients with this chronic skin condition.